InspireMD (NSPR) : During the past 4 weeks, traders have been relatively bearish on InspireMD (NSPR), hence the stock is down -54.46% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -14.11% relative to the S&P 500. The 4-week change in the price of the stock is -52.47% and the stock has fallen -12.82% in the past 1 week. The stock has recorded a 20-day Moving Average of 40.19% and the 50-Day Moving Average is 53.22%.
InspireMD (NYSEMKT:NSPR): The stock opened at $0.19 on Friday but the bulls could not build on the opening and the stock topped out at $0.19 for the day. The stock traded down to $0.17 during the day, due to lack of any buying support eventually closed down at $0.18 with a loss of -3.63% for the day. The stock had closed at $0.18 on the previous day. The total traded volume was 2,045,390 shares.
The company Insiders own 24.28% of InspireMD shares according to the proxy statements. Institutional Investors own 9.55% of InspireMD shares. During last six month period, the net percent change held by insiders has seen a change of 303.47%. In a related news, Loughlin James J, director of Inspiremd, Inc., executed a transaction worth $29,500 on March 21, 2016. A total of 50,000 shares were purchased at an average price of $0.59. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
InspireMD, Inc. is a medical device company. The Company is focused on the development and commercialization of its MicroNet stent platform technology for the treatment of complex coronary and vascular disease. The Companys MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Companys MGuard coronary products combining MicroNet and a bare-metal stent (MGuard Prime Embolic Protection Stent (EPS)) are marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The Companys second product CGuard carotid embolic prevention system (EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. The Company is also developing a pipeline of other products and additional applications by leveraging its MicroNet technology.